Additionally, PI3K/Akt/mTOR signaling is dysregulated in renal cell carcinomas (RCCs), and mTOR inhibitors such as temsirolimus and everolimus are important therapeutic options for RCC treatment [23]. The gene discussed is MTOR; the disease is renal cell carcinoma.